Ahead of Myriad (MYGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Core Insights - Wall Street analysts expect Myriad Genetics (MYGN) to report a quarterly loss of -$0.02 per share, reflecting a year-over-year decline of 166.7% [1] - Revenues are projected to be $207.59 million, which is a decrease of 1.4% compared to the same quarter last year [1] - There have been no revisions in the consensus EPS estimate over the last 30 days, indicating stability in analysts' forecasts [1] Revenue Estimates - The consensus estimate for 'Revenue by core product - Prenatal' is $47.02 million, representing a year-over-year increase of 4.7% [3] - 'Revenue by core product - Hereditary Cancer' is expected to reach $94.87 million, suggesting a slight increase of 0.6% year over year [4] - 'Revenue by core product - Pharmacogenomics' is forecasted at $36.87 million, indicating a decline of 9.2% from the prior-year quarter [4] - 'Revenue by core product - Tumor Profiling' is estimated to be $28.59 million, reflecting a decrease of 7.2% year over year [4] Stock Performance - Over the past month, shares of Myriad have declined by 20.8%, while the Zacks S&P 500 composite has only decreased by 1.3% [5] - MYGN currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance in the near future [5]